migraine

Novartis announces AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention

Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability, affecting more than 10% of people worldwide – within the overall migraine population, people with chronic migraine experience the greatest impact on daily activities […]

Novartis announces AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention Read More »

Road trip 2017- Migraine Association of Ireland

The Migraine Association of Ireland is going on a ‘road-trip’! In October of 2017 they will be traveling the country to locations they seldom get the chance to visit and holding information stands in various places. So keep an eye out for them if you live in the following counties; Galway, Mayo, Sligo, Waterford, Wexford, Carlow, Kilkenny,  They will be

Road trip 2017- Migraine Association of Ireland Read More »

Scroll to Top
Search
Close this search box.

Join our newsletter.

Don't miss out on any updates! Join our community and discover 

the latest research, treatments, and events on migraine.
Subscribe now!